CJC-1295 (with DAC) vs P21 (Cerebrolysin Analog)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

CJC-1295 (with DAC)P21 (Cerebrolysin Analog)
CategoryPeptidesPeptides
Standard DoseResearch indicates 2 mg administered once weekly via subcutaneous injection.Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.
TimingEvening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.Morning dosing preferred for cognitive effects.
Cycle Duration12-24 week cycles with 4-8 week breaks between cycles.4-8 week cycles with 4-week rest periods.
Evidence Levelmoderate_humananimal_plus_anecdotal

Mechanism

CJC-1295 with DAC (Drug Affinity Complex) is a synthetic 30-amino acid GHRH analog with four amino acid substitutions rendering it resistant to DPP-IV proteolytic inactivation. The DAC moiety covalently binds to endogenous serum albumin via a disulfide bond after injection, extending half-life to 5.8-8.1 days. It stimulates pulsatile GH release from anterior pituitary somatotrophs through GHRH receptor activation, producing dose-dependent 2-10 fold increases in plasma GH for 6+ days and 1.5-3 fold IGF-1 elevations for 9-11 days per injection.

Standard Dosing

Research indicates 2 mg administered once weekly via subcutaneous injection.

Timing

Evening administration preferred (aligns with natural GH pulsatility). Inject on an empty stomach — food (especially carbohydrates) blunts GH release.

Cycle Duration

12-24 week cycles with 4-8 week breaks between cycles.

Side Effects

  • Water retention
  • Tingling/numbness in extremities
  • Joint pain
  • Increased hunger
  • Injection site reactions
  • Potential insulin resistance with prolonged use

Contraindications

  • Active cancer or history of cancer
  • Diabetic retinopathy
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6

Mechanism

P21 is a tetrapeptide (DGGL — Asp-Gly-Gly-Leu) derived from the most active region of ciliary neurotrophic factor (CNTF, residues 148-151), identified through reverse engineering of Cerebrolysin. An adamantylated glycine enhances BBB permeability and metabolic stability. P21 works through LIF/STAT3 pathway inhibition, BDNF/TrkB/CREB signaling enhancement, and restoration of synaptic proteins (synaptophysin, synapsin I) and glutamate receptors. It promotes neurogenesis and maturation of newborn neurons in the dentate gyrus.

Standard Dosing

Research indicates 750 mcg-1 mg daily via intranasal administration or subcutaneous injection.

Timing

Morning dosing preferred for cognitive effects.

Cycle Duration

4-8 week cycles with 4-week rest periods.

Side Effects

  • Mild headache
  • Nasal irritation (intranasal)
  • Increased appetite (CNTF pathway modulation)
  • Vivid dreams

Contraindications

  • Pregnancy and breastfeeding
  • Active seizure disorders

Best Stacking Partners

SemaxSelankDihexa

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →